Che-Kai Tsao, MD

Che-Kai Tsao, MD, discusses key updates from the phase 3 CheckMate 9ER trial, and how these data clarify the role of nivolumab plus cabozantinib as a new standard of care in renal cell carcinoma.

Che-Kai Tsao, MD, discusses the investigation of cabozantinib in combination with nivolumab and ipilimumab in patients with renal cell carcinoma.

Che-Kai Tsao, MD, discusses first-line treatment approaches for patients with clear cell renal cell carcinoma.

Che-Kai Tsao, MD, shares strategies to improve outcomes in renal cell carcinoma.

Che-Kai Tsao, MD, shares strategies to improve outcomes in renal cell carcinoma.

Che-Kai Tsao, MD, discusses the rationale behind staging disease, especially in the context of when patients are diagnosed with renal cell carcinoma.